Lymphoplasmacyte-rich meningioma with hematologic signs and PD-L1 over-expression
Gabriele Gaggero; Michela Campora; Davide Taietti; Giannamaria Cerruti; Enrico Lo Bue; Monica Truffelli; Marco Ceraudo; Pietro Fiaschi
Abstract
Keywords
References
1 Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro-oncol. 2021;23(12, Suppl 2):iii1-105.
2 IARC Publications. Central Nervous System Tumours: WHO Classification of Tumours. 5th. Lyon: IARC Publications; 2021 [cited 2022 June 25]. Available from:
3 Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4-23.
4 Liu JL, Zhou JL, Ma YH, Dong C. An analysis of the magnetic resonance imaging and pathology of intracal lymphoplasmacyte-rich meningioma. Eur J Radiol. 2012;81(5):968-73.
5 Firdaus, M., Gill AS, Andriani R et al. A rare cystic lymphoplasmacyte-rich meningioma: a case report and review of the literature. Surg Neurol Int 2020;11:391.
6 Zhu HD, Xie Q, Gong Y, et al. Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a systematic literature review. Int J Clin Exp Med. 2013;6(7):504-15. PMid:23936588.
7 Yongjun L, Xin L, Qiu S, Jun-Lin Z. Imaging findings and clinical features of intracal lymphoplasmacyte-rich meningioma. J Craniofac Surg. 2015;26(2):e132-7.
8 Lal A, Dahiya S, Gonzales M, et al. IgG4 overexpression is rare in meningiomas with a prominent inflammatory component: a review of 16 cases. Brain Pathol. 2014;24(4):352-9.
9 Tao X, Wang K, Dong J, et al. Clinical, radiologic, and pathologic features of 56 cases of intracranial lymphoplasmacyte-rich meningioma. World Neurosurg. 2017;106:152-64.
10 de Almeida GB, Januário G. Lymphoplasmacyte-rich meningioma: a rare histologic variant of benign meningioma with atypical bone invasion. Radiol Case Rep. 2022;17(3):922-7.
11 Wang H, He B, Wang Y, Chen H, Huang S, Xu J. Lymphoplasmacyte-rich meningioma in the central nervous system: an unusual case report. Medicine (Baltimore). 2021;100(52):e27991.
12 Li J, Zan X, Feng M, Deng X, Zhang S, Liu W. Case report: creeping growth in lymphoplasmacyte-rich meningioma—a radiologic variant. Front Surg. 2021;8:775560.
13 Kurmi DJ, Sharma A, Mittal RS, Singhvi S. Lymphoplasmacyte-rich meningioma with invasion of bone: a case report and review of literature. Asian J Neurosurg. 2016;11(4):448.
14 Nohara H, Furuya K, Kawahara N, et al. Lymphoplasmacyte-rich meningioma with atypical invasive nature. Neurol Med Chir (Tokyo). 2007;47(1):32-5.
15 Banerjee AK, Blackwood W. A subfrontal tumour with the features of plasmocytoma and meningioma. Acta Neuropathol. 1971;18(1):84-8.
16 Weidenheim KM, Campbell WG Jr, Goldman HW. Atypical monoclonal plasma cell hyperplasia of the central nervous system: precursor of plasmacytoma with evolutionary considerations. Neurosurgery. 1989;24(3):429-34.
17 Gregorios JB, Bay JW, Dudley AW Jr. Extramedullary hematopoiesis in a malignant meningioma. Neurosurgery. 1983;13(4):447-51.
18 Bruno MC, Ginguené C, Santangelo M, et al. Lymphoplasmacyte rich meningioma: a case report and review of the literature. J Neurosurg Sci. 2004;48(3):117-24, discussion 124. PMid:15557881.
19 Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncol. 2021;23(8):1231-51.
20 Gi H, Nagao S, Yoshizumi H, et al. Meningioma with hypergammaglobulinemia. Case report. J Neurosurg. 1990;73(4):628-9.
21 Kepes JJ, Chen WY, Connors MH, Vogel FS. “Chordoid” meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the castleman syndrome. A report of seven cases. Cancer. 1988;62(2):391-406.
22 Stam FC, van Alphen HAM, Boorsma DM. Meningioma with conspicuous plasma cell components. A histopathological and immunohistochemical study. Acta Neuropathol. 1980;49(3):241-3.
23 Johnson MD. PD-L1 expression in meningiomas. J Clin Neurosci. 2018;57:149-51.
24 Han SJ, Reis G, Kohanbash G, et al. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016;130(3):543-52.
25 Mair MJ, Pajenda S, Ilhan-Mutlu A, et al. Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. ESMO Open. 2020;5(6):e000863.
26 Du Z, Abedalthagafi M, Aizer AA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6(7):4704-16.
27 Karimi S, Mansouri S, Mamatjan Y, et al. Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression.
28 Li YD, Veliceasa D, Lamano JB, et al. Systemic and local immunosuppression in patients with high-grade meningiomas. Cancer Immunol Immunother. 2019;68(6):999-1009.
29 Karimi S, Mansouri S, Nassiri F, et al. Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status. J Neurooncology. 2021;151:443-9.
30 Tsukamoto M, Imai K, Ishimoto T, et al. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Cancer Sci. 2019;110(1):310-20. PMid:30426611.
31 Ding Y, Qiu L, Xu Q, Song L, Yang S, Yang T. Relationships between tumor microenvironment and clinicopathological parameters in meningioma. Int J Clin Exp Pathol. 2014;7(10):6973-9. PMID: 25400783.
32 van Kempen LCLT, Ruiter DJ, van Muijen GNP, Coussens LM. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol. 2003;82(11):539-48.
33 Yu P, Rowley DA, Fu YX, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol. 2006;18(2):226-31.
34 Ladányi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 2015;28(5):490-500.
35 Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18(24):6758-70.
36 Liao Y, Ou J, Deng J, et al. Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer. Med Oncol. 2013;30(4):727.
37 Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93-103.
38 Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67(18):8900-5.
39 Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168(9):4272-6.
40 Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295-307.
41 Nakano O, Sato M, Naito Y, et al. Proliferative activity of Intratumoral CD8 T-Lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of Antitumor Immunity 1. Cancer Res. 2001;61(13):5132-6. PMid:11431351.
42 Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185(9):4977-82.
43 Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: working together to promote patient survival. OncoImmunology. 2012;1(9):1623-5.
44 Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104(10):3967-72.
45 Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538-43.
46 Liao Y, Ou J, Deng J, et al. Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer. Med Oncol. 2013;30(4):727.
47 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
Submitted date:
06/25/2022
Accepted date:
07/16/2022
Publication date:
08/08/2022
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email